Vanda launches NEREUS motion sickness drug commercially in U.S. with DTC platform

• NEREUS (tradipitant), an FDA‑approved treatment for motion sickness, is now available nationwide across the U.S.
• Vanda launched a new direct‑to‑consumer ordering platform to support NEREUS access for patients.
• Company disclosed cash‑pay pricing for NEREUS as part of the commercial rollout.

https://finviz.com/quote?t=VNDA&p=d